Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Significance: Targeting myeloid cells represents a promising strategy to augment antitumor immunity and overcome resistance to existing T cell-targeting therapies. However myeloid checkpoints that can be effectively used as immunotherapy targets are still lacking. Here, we demonstrate the therapeutic potential of targeting Siglec-7 and Siglec-9 to enhance antitumor immunity in vivo. Using an immunocompetent mouse model humanized for Siglec-7/9, we show that these receptors inhibit the endogenous antitumor immune response in a tissue-specific manner. These Siglecs also restrict the response to tumor-targeting and checkpoint-targeting antibodies, highlighting their significance in combinatorial approaches to immunotherapy. Finally, we show that Siglec-7/9 blockade can significantly reduce tumor burden in vivo, supporting the use of antibodies targeting Siglec-7/9 to therapeutically enhance antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Wiederschain, G. Y. (2009) · Biochemistry (Moscow) · doi:10.1134/s0006297909090156 · Cited by 4,083
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Varki, A. P., Cummings, R. D., Esko, J. D., Freeze, H. H., Stanley, P., Bertozzi, C. R., Hart, G. W., & Etzler, M. E. (1999) · Cited by 2,384
Siglecs and their roles in the immune system
Crocker, P. R., Paulson, J. C., & Varki, A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2056 · Cited by 2,031 · cited 2×
“Based on sequence similarity, they can be divided into conserved Siglecs (Siglec-1, -2, -4, and -15), and rapidly evolving CD33-related Siglecs (CD33 or Siglec-3, Siglec-5, -6, -7, -8, -9, -10, -11, -12, -14, and -16) (17).”
BackgroundDeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Coffelt, S. B., Kersten, K., Doornebal, C. W., Weiden, J., Vrijland, K., Hau, C.-S., Verstegen, N. J. M., Ciampricotti, M., Hawinkels, L. J. A. C., Jonkers, J., et al. (2015) · Nature · doi:10.1038/nature14282 · Cited by 1,703
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
Barkal, A. A., Brewer, R. E., Markovic, M., Kowarsky, M., Barkal, S. A., Zaro, B. W., Krishnan, V., Hatakeyama, J., Dorigo, O., Barkal, L. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1456-0 · Cited by 1,385
Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R., & Chandra, A. B. (2020) · Cancers · doi:10.3390/cancers12030738 · Cited by 1,196
Siglec-mediated regulation of immune cell function in disease
Macauley, M. S., Crocker, P. R., & Paulson, J. C. (2014) · Nature Reviews Immunology · doi:10.1038/nri3737 · Cited by 1,122 · cited 11×
“Together with our in vivo data, this suggests that anti–Siglec-7 and Siglec-9 antibodies function by preventing polarization of macrophages into TAMs and thus reprogramming the immune-suppressive TME.”
BackgroundInfluentialDivergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037 · cited 1×
“The variable region of each antibody was cloned into a mouse IgG1-D265A Fc backbone, which lacks detectable FcγR binding (39).”
BackgroundSelf-citationCassetta, L., Fragkogianni, S., Sims, A. H., Swierczak, A., Forrester, L. M., Zhang, H., Soong, D. Y. H., Cotechini, T., Anur, P., Lin, E. Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.009 · Cited by 920 · cited 1×
“Upregulation of sialoglycan expression, however, is commonly found on various tumor types (12, 13, 19, 20), and numerous studies have indicated that their interaction with Siglecs can inhibit immune cell activity, thus contributing to an immunosuppressive tumor microenvironment (TME) (21, 22).”
BackgroundTumor entrained neutrophils inhibit seeding in the premetastatic lung
Granot, Z., Henke, E., Comen, E. A., King, T. A., Norton, L., & Benezra, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.012 · Cited by 782 · cited 1×
“In the context of the lung, previous studies have showed that neutrophils can have an antitumor effect by inhibiting lung colonization (40).”
BackgroundSiglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
Wang, J., Sun, J., Liu, L. N., Flies, D. B., Nie, X., Toki, M., Zhang, J., Song, C., Zarr, M., Zhou, X., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0374-x · Cited by 679 · cited 1×
“Currently, just one such antibody is being evaluated in clinical trials, an anti–Siglec-15 antibody (NC318) that reverses T cell suppression by blocking the interaction between macrophages and T cells (14).”
BackgroundFcγRIV: A Novel FcR with Distinct IgG Subclass Specificity
Nimmerjahn, F., Bruhns, P., Horiuchi, K., & Ravetch, J. V. (2005) · Immunity · doi:10.1016/j.immuni.2005.05.010 · Cited by 660
Self-citationMelanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Kleffel, S., Posch, C., Barthel, S. R., Mueller, H., Schlapbach, C., Guenova, E., Elco, C. P., Lee, N., Juneja, V. R., Zhan, Q., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.052 · Cited by 639 · cited 1×
“Once B16 or B16-FUT3 tumors are palpable, they are refractory to single-agent therapy (35, 36).”
BackgroundGeorgoudaki, A.-M., Prokopec, K. E., Boura, V. F., Hellqvist, E., Sohn, S., Östling, J., Dahan, R., Harris, R. A., Rantalainen, M., Klevebring, D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.084 · Cited by 609
Self-citationResistance to PD1/PDL1 checkpoint inhibition
O'Donnell, J. S., Long, G. V., Scolyer, R. A., Teng, M. W. L., & Smyth, M. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.007 · Cited by 572
Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion
Hudak, J. E., Canham, S. M., & Bertozzi, C. R. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1388 · Cited by 485 · cited 1×
“However, most of our mechanistic understanding of how these two Siglecs contribute to tumor progression comes from in vitro studies that lack the complexity of cellular and morphological diversity, and the interplay of soluble and cellular immune mediators found in vivo (24, 27, 30, 31).”
BackgroundSialic acids in cancer biology and immunity
Pearce, O. M. T., & Läubli, H. (2016) · Glycobiology · doi:10.1093/glycob/cwv097 · Cited by 470
Jandus, C., Boligan, K. F., Chijioke, O., Liu, H., Dahlhaus, M., Démoulins, T., Schneider, C., Wehrli, M., Hunger, R. E., Baerlocher, G. M., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci65899 · Cited by 439 · cited 1×
“However, most of our mechanistic understanding of how these two Siglecs contribute to tumor progression comes from in vitro studies that lack the complexity of cellular and morphological diversity, and the interplay of soluble and cellular immune mediators found in vivo (24, 27, 30, 31).”
BackgroundFcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
Dahan, R., Sega, E., Engelhardt, J., Selby, M., Korman, A. J., & Ravetch, J. V. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.004 · Cited by 409
Self-citationBeatson, R., Tajadura-Ortega, V., Achkova, D., Picco, G., Tsourouktsoglou, T.-D., Klausing, S., Hillier, M., Maher, J., Noll, T., Crocker, P. R., et al. (2016) · Nature Immunology · doi:10.1038/ni.3552 · Cited by 378 · cited 1×
“Previous in vitro studies have shown that engagement of Siglec-9 by a cancer-specific mucin induces a tumor-associated macrophage (TAM) phenotype on Siglec-9–expressing macrophages, and that this phenotypic change can be rescued by blockade of Siglec-9 (26).”
BackgroundLi, F., & Ravetch, J. V. (2011) · Science · doi:10.1126/science.1206954 · Cited by 335 · cited 1×
“The variable heavy and light regions of anti–Siglec-7 (clone 1E8) and anti–Siglec-9 (clone mAbA) antibodies (described in patents WO/2017/040301Al, and WO/2017/153433Al, respectively) were synthesized (IDT) and subcloned into mammalian expression vectors with a mouse IgG1 heavy chain containing a D265A point mutation,…”
MethodSelf-citationSelf-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Stanczak, M. A., Siddiqui, S. S., Trefny, M. P., Thommen, D. S., Boligan, K. F., von Gunten, S., Tzankov, A., Tietze, L., Lardinois, D., Heinzelmann-Schwarz, V., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120612 · Cited by 296
The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice
Engle, D. D., Tiriac, H., Rivera, K. D., Pommier, A., Whalen, S., Oni, T. E., Alagesan, B., Lee, E. J., Yao, M. A., Lucito, M. S., et al. (2019) · Science · doi:10.1126/science.aaw3145 · Cited by 287
Chen, S., Lee, L.-F., Fisher, T. S., Jessen, B., Elliott, M., Evering, W., Logronio, K., Tu, G. H., Tsaparikos, K., Li, X., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0118 · Cited by 277 · cited 1×
“Once B16 or B16-FUT3 tumors are palpable, they are refractory to single-agent therapy (35, 36).”
BackgroundSialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell–Mediated Tumor Immunity
Büll, C., Boltje, T. J., Balneger, N., Weischer, S. M., Wassink, M., van Gemst, J. J., Bloemendal, V. R., Boon, L., van der Vlag, J., Heise, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3376 · Cited by 268
Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis
Dellon, E. S., Peterson, K. A., Murray, J. A., Falk, G. W., Gonsalves, N., Chehade, M., Genta, R. M., Leung, J., Khoury, P., Klion, A. D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012047 · Cited by 268 · cited 1×
“For example, Inotuzumab (anti–Siglec-2) for B cell acute lymphocytic leukemia, Gemtuzumab (anti–Siglec-3) for acute myeloid leukemia, and Lirentelimab (anti–Siglec-8) for eosinophilic gastritis (41, 42).”
BackgroundLäubli, H., Pearce, O. M. T., Schwarz, F., Siddiqui, S. S., Deng, L., Stanczak, M. A., Deng, L., Verhagen, A., Secrest, P., Lusk, C., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409580111 · Cited by 228 · cited 5×
“Previous in vivo studies on the impact of Siglec-9 and its murine homolog Siglec-E on tumor progression have relied on the use of mixed background murine models and have generated contradictory results (12).”
BackgroundInfluentialvon Gunten, S., Yousefi, S., Seitz, M., Jakob, S. M., Schaffner, T., Seger, R., Takala, J., Villiger, P. M., & Simon, H.-U. (2005) · Blood · doi:10.1182/blood-2004-10-4112 · Cited by 217 · cited 1×
“However, most of our mechanistic understanding of how these two Siglecs contribute to tumor progression comes from in vitro studies that lack the complexity of cellular and morphological diversity, and the interplay of soluble and cellular immune mediators found in vivo (24, 27, 30, 31).”
BackgroundMyeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer
Srivastava, M. K., Zhu, L., Harris-White, M., Kar, U., Huang, M., Johnson, M. F., Lee, J. M., Elashoff, D., Strieter, R., Dubinett, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040677 · Cited by 214
AN ALTERATION IN TUMOR HISTOCOMPATIBILITY INDUCED BY NEURAMINIDASE
Sanford, B. H. (1967) · Transplantation · doi:10.1097/00007890-196709000-00005 · Cited by 206 · cited 11×
“Together with our in vivo data, this suggests that anti–Siglec-7 and Siglec-9 antibodies function by preventing polarization of macrophages into TAMs and thus reprogramming the immune-suppressive TME.”
BackgroundInfluentialEisinger, S., Sarhan, D., Boura, V. F., Ibarlucea-Benitez, I., Tyystjärvi, S., Oliynyk, G., Arsenian-Henriksson, M., Lane, D., Wikström, S. L., Kiessling, R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2015343117 · Cited by 173
Self-citationHaas, Q., Boligan, K. F., Jandus, C., Schneider, C., Simillion, C., Stanczak, M. A., Haubitz, M., Jafari, S. M. S., Zippelius, A., Baerlocher, G. M., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0505 · Cited by 173
Läubli, H., Alisson-Silva, F., Stanczak, M. A., Siddiqui, S. S., Deng, L., Verhagen, A., Varki, N., & Varki, A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.593129 · Cited by 116 · cited 1×
“However, most of our mechanistic understanding of how these two Siglecs contribute to tumor progression comes from in vitro studies that lack the complexity of cellular and morphological diversity, and the interplay of soluble and cellular immune mediators found in vivo (24, 27, 30, 31).”
BackgroundSiglecs as sensors of self in innate and adaptive immune responses
Paulson, J. C., Macauley, M. S., & Kawasaki, N. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06362.x · Cited by 113 · cited 1×
“” The Siglec-sialoglycan axis is therefore an inhibitory pathway that protects the body from autoimmunity (17, 18).”
BackgroundFcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
Dahan, R., Sega, E. I., Engelhardt, J., Selby, M., Korman, A. J., & Ravetch, J. V. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.011 · Cited by 98 · cited 1×
“Expression plasmids for anti–PD-1 (clone RMP1-14, mIgG1 D265A) and anti-sLeA (clone 5B1, mIgG2a) antibodies were previously generated in the laboratory (33, 45).”
MethodSelf-citationOhta, M., Ishida, A., Toda, M., Akita, K., Inoue, M., Yamashita, K., Watanabe, M., Murata, T., Usui, T., & Nakada, H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.10.079 · Cited by 94
Modulation of immune cell reactivity with cis -binding Siglec agonists
Delaveris, C. S., Chiu, S. H., Riley, N. M., & Bertozzi, C. R. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012408118 · Cited by 74
The Roles of Siglec7 and Siglec9 on Natural Killer Cells in Virus Infection and Tumour Progression
Zheng, Y., Ma, X., Su, D., Zhang, Y., Yu, L., Jiang, F., Zhou, X. M., Feng, Y., & Ma, F. (2020) · Journal of Immunology Research · doi:10.1155/2020/6243819 · Cited by 66 · cited 1×
“Siglec-7 and Siglec-9 are closely related: they share ∼98% amino acid sequence similarity, show a similar expression pattern across immune cells, and have similar ligand affinity (29).”
BackgroundAntibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways
Weitzenfeld, P., Bournazos, S., & Ravetch, J. V. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128437 · Cited by 59 · cited 12×
“B16-FUT3 and EL4-FUT3 cells were generated as previously described (33).”
BackgroundMethodResultSelf-citationCurrent Status on Therapeutic Molecules Targeting Siglec Receptors
Lenza, M. P., Atxabal, U., Oyenarte, I., Jiménez‐Barbero, J., & Ereño‐Orbea, J. (2020) · Cells · doi:10.3390/cells9122691 · Cited by 56
Cao, H., de Bono, B., Belov, K., Wong, E. S. W., Trowsdale, J., & Barrow, A. D. (2009) · Immunogenetics · doi:10.1007/s00251-009-0372-0 · Cited by 51 · cited 1×
“In contrast to conserved Siglecs, CD33-related Siglecs do not have clear mammalian orthologs and exhibit a broader expression across the myeloid and lymphoid compartments (23).”
Background
Cited by
Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Mei, Y., Wang, X., Zhang, J., Liu, D., He, J., Huang, C., Liao, J., Wang, Y., Feng, Y., Li, H., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00598-9 · Cited by 224
Timperi, E., Croizer, H., Khantakova, D., Rana, M., Molgora, M., Guerriero, J. L., Mechta-Grigoriou, F., & Romano, E. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1690 · Cited by 49
The intriguing roles of Siglec family members in the tumor microenvironment
Jiang, K.-Y., Qi, L.-L., Kang, F.-B., & Wang, L. (2022) · Biomarker Research · doi:10.1186/s40364-022-00369-1 · Cited by 43
“However, a study [67] demonstrated that human Siglec-7/9 and Siglec-E inhibit the endogenous antitumor immune response as well as responses to tumor-targeting and immune checkpoint-inhibiting antibodies in vivo.”
Background
Metadata
- Authors
- Ibarlucea-Benitez, I., Weitzenfeld, P., Smith, P., & Ravetch, J. V.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2021-06-21
- Volume
- 118
- Issue
- 26
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W3174289113
- Cited by
- 177
- References
- 46
- FWCI
- 8.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.